Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer-Reference-Cited by-同舟云学术

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer

Published:2014-06-30 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Kunath Frank¹²³,Grobe Henrik R⁴,Rücker Gerta⁵,Motschall Edith⁵,Antes Gerd⁶,Dahm Philipp⁷⁸,Wullich Bernd¹³,Meerpohl Joerg J²

Affiliation:

1. University of Erlangen; Department of Urology; Krankenhausstrasse 12 Erlangen Germany 91054

2. Medical Center - University of Freiburg; German Cochrane Centre; Freiburg Germany

3. Deutsche Gesellschaft für Urologie e.V.; UroEvidence; Düsseldorf, Berlin Germany

4. University Medical Center Freiburg; Department of General and Visceral Surgery & German Cochrane Centre; Hugstetter Str. 55 Freiburg Germany 79106

5. Medical Center - University of Freiburg; Center for Medical Biometry and Medical Informatics; Stefan-Meier-Str. 26 Freiburg Germany 79104

6. Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg; German Cochrane Centre; Berliner Allee 29 Freiburg Germany 79110

7. University of Florida; Department of Urology; Box 100247 Room N203 Gainesville Florida USA 32610-0247

8. Malcom Randall Veterans Affairs Medical Center; Gainesville Florida USA

Publisher

Wiley

Subject

Pharmacology (medical)

Reference191 articles.

1. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma;Boccon-Gibod;European Urology,1997

2. Anti-androgens increase N-Terminal pro-BNP in men with prostate cancer;Dockery;Clinical Endocrinology,2008

3. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer;Dockery;Journal of Andrology,2009

4. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma;Sciarra;Urology,2004

5. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer;Sieber;Journal of Urology,2004

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term disease stability with bicalutamide in a man with aggressive angiomyxoma: case report and state of art;Frontiers in Oncology;2024-01-16

2. Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8+ T lymphocytes, NK‐cells, and high frequency of CD73+ stromal cells;Cancer Reports;2023-04-24

3. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance;Progrès en Urologie;2022-11

4. Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial;International Journal of Radiation Oncology*Biology*Physics;2022-06

5. Therapie des hormonsensitiven, metastasierten Adenokarzinoms der Prostata;Journal für Urologie und Urogynäkologie/Österreich;2022-05-30